{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:16:23Z","timestamp":1788516983939,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00169-8","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:52:49Z","timestamp":1788515569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape"],"prefix":"10.1007","volume":"61","author":[{"given":"Dae-Ho","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"15","key":"169_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMra2033982","volume":"385","author":"S Berentsen","year":"2021","unstructured":"Berentsen S, Barcellini W. Autoimmune hemolytic anemias. N Engl J Med. 2021;385(15):1407\u201319. https:\/\/doi.org\/10.1056\/NEJMra2033982.","journal-title":"N Engl J Med"},{"key":"169_CR2","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","volume":"41","author":"U Jager","year":"2020","unstructured":"Jager U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev. 2020;41:100648. https:\/\/doi.org\/10.1016\/j.blre.2019.100648.","journal-title":"Blood Rev"},{"issue":"3","key":"169_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3324\/haematol.2013.091702","volume":"99","author":"U Randen","year":"2014","unstructured":"Randen U, Troen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497\u2013504. https:\/\/doi.org\/10.3324\/haematol.2013.091702.","journal-title":"Haematologica"},{"key":"169_CR4","doi-asserted-by":"publisher","first-page":"1490130","DOI":"10.3389\/frhem.2025.1490130","volume":"4","author":"D Cella","year":"2025","unstructured":"Cella D, Hill QA, Karaouni A, et al. FACIT-Fatigue scale in patients with cold agglutinin disease: psychometric validation and estimation of clinically meaningful change. Front Hematol. 2025;4:1490130. https:\/\/doi.org\/10.3389\/frhem.2025.1490130.","journal-title":"Front Hematol"},{"issue":"4","key":"169_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood.2020005674","volume":"136","author":"S Berentsen","year":"2020","unstructured":"Berentsen S, Barcellini W, D\u2019Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136(4):480\u20138. https:\/\/doi.org\/10.1182\/blood.2020005674.","journal-title":"Blood"},{"issue":"4","key":"169_CR6","first-page":"460","volume":"91","author":"S Berentsen","year":"2006","unstructured":"Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460\u20136.","journal-title":"Haematologica"},{"issue":"19","key":"169_CR7","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","volume":"124","author":"W Barcellini","year":"2014","unstructured":"Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930\u20136. https:\/\/doi.org\/10.1182\/blood-2014-06-583021.","journal-title":"Blood"},{"issue":"20","key":"169_CR8","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/bloodadvances.2019000476","volume":"3","author":"LC Bylsma","year":"2019","unstructured":"Bylsma LC, Gulbech Ording A, Rosenthal A, et al. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv. 2019;3(20):2980\u20135. https:\/\/doi.org\/10.1182\/bloodadvances.2019000476.","journal-title":"Blood Adv"},{"issue":"13","key":"169_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/bloodadvances.2017004390","volume":"1","author":"M Mullins","year":"2017","unstructured":"Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839\u201348. https:\/\/doi.org\/10.1182\/bloodadvances.2017004390.","journal-title":"Blood Adv"},{"issue":"7","key":"169_CR10","doi-asserted-by":"publisher","first-page":"E262","DOI":"10.1002\/ajh.26196","volume":"96","author":"DL Hansen","year":"2021","unstructured":"Hansen DL, Berentsen S, Fattizzo B, Hansen PL, Barcellini W, Frederiksen H. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy. Am J Hematol. 2021;96(7):E262\u20135. https:\/\/doi.org\/10.1002\/ajh.26196.","journal-title":"Am J Hematol"},{"key":"169_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood.V130.Suppl_1.928.928","volume":"130","author":"C Broome","year":"2017","unstructured":"Broome C, Cunningham JM, Mullins M, et al. Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort. Blood. 2017;130:928. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.928.928.","journal-title":"Blood"},{"issue":"4","key":"169_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1600-0609.1999.tb01887.x","volume":"63","author":"E Ulvestad","year":"1999","unstructured":"Ulvestad E, Berentsen S, B\u00f8 K, Shammas FV. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol. 1999;63(4):259\u201366. https:\/\/doi.org\/10.1111\/j.1600-0609.1999.tb01887.x.","journal-title":"Eur J Haematol"},{"issue":"5","key":"169_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1699-0463.1997.tb00581.x","volume":"105","author":"S Berentsen","year":"1997","unstructured":"Berentsen S, B\u00f8 K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the \u201cidiopathic\u201d type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105(5):354\u201362. https:\/\/doi.org\/10.1111\/j.1699-0463.1997.tb00581.x.","journal-title":"APMIS"},{"issue":"9","key":"169_CR14","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2016.146126","volume":"101","author":"A Ma\u0142ecka","year":"2016","unstructured":"Ma\u0142ecka A, Tr\u00f8en G, Tierens A, et al. Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity. Haematologica. 2016;101(9):e361\u20134. https:\/\/doi.org\/10.3324\/haematol.2016.146126.","journal-title":"Haematologica"},{"key":"169_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/jbm.S177621","volume":"10","author":"S Berentsen","year":"2019","unstructured":"Berentsen S, R\u00f6th A, Randen U, Jilma B, Tj\u00f8nnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med. 2019;10:93\u2013103. https:\/\/doi.org\/10.2147\/jbm.S177621.","journal-title":"J Blood Med"},{"issue":"7","key":"169_CR16","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"4","key":"169_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood.2023022549","volume":"145","author":"E Roman","year":"2025","unstructured":"Roman E, Fattizzo B, Shum M, et al. Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia. Blood. 2025;145(4):397\u2013408. https:\/\/doi.org\/10.1182\/blood.2023022549.","journal-title":"Blood"},{"issue":"26","key":"169_CR18","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","volume":"123","author":"J Shi","year":"2014","unstructured":"Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123(26):4015\u201322. https:\/\/doi.org\/10.1182\/blood-2014-02-556027.","journal-title":"Blood"},{"issue":"19","key":"169_CR19","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","volume":"2","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th A, Bommer M, H\u00fcttmann A, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2(19):2543\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2018024190.","journal-title":"Blood Adv"},{"issue":"1","key":"169_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00078-2","volume":"60","author":"NM Nasr","year":"2025","unstructured":"Nasr NM, Ayad AA, Abdelghaffar NK, Mohamed MS. The correlation between serum complement levels and clinical presentation in Egyptian immune thrombocytopenia patients. Blood Res. 2025;60(1):29. https:\/\/doi.org\/10.1007\/s44313-025-00078-2.","journal-title":"Blood Res"},{"issue":"1","key":"169_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1182\/hematology.2025000718","volume":"2025","author":"S Berentsen","year":"2025","unstructured":"Berentsen S. Diagnosis and management of cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2025;2025(1):295\u2013304. https:\/\/doi.org\/10.1182\/hematology.2025000718.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"169_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.14478","volume":"176","author":"QA Hill","year":"2017","unstructured":"Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3):395\u2013411. https:\/\/doi.org\/10.1111\/bjh.14478.","journal-title":"Br J Haematol"},{"issue":"12","key":"169_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/14712598.2023.2274912","volume":"23","author":"F Cavallaro","year":"2023","unstructured":"Cavallaro F, Barcellini W, Fattizzo B. Antibody based therapeutics for autoimmune hemolytic anemia. Expert Opin Biol Ther. 2023;23(12):1227\u201337. https:\/\/doi.org\/10.1080\/14712598.2023.2274912.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"169_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","volume":"38","author":"L Connelly-Smith","year":"2023","unstructured":"Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38(2):77\u2013278. https:\/\/doi.org\/10.1002\/jca.22043.","journal-title":"J Clin Apher"},{"issue":"8","key":"169_CR25","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","volume":"103","author":"S Berentsen","year":"2004","unstructured":"Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925\u20138. https:\/\/doi.org\/10.1182\/blood-2003-10-3597.","journal-title":"Blood"},{"issue":"4","key":"169_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","volume":"130","author":"S Berentsen","year":"2017","unstructured":"Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130(4):537\u201341. https:\/\/doi.org\/10.1182\/blood-2017-04-778175.","journal-title":"Blood"},{"issue":"1","key":"169_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s44313-025-00109-y","volume":"60","author":"K Ito","year":"2025","unstructured":"Ito K, Kitagawa T, Motohashi S, Hirano K, Sekiguchi N. Durable responses and favorable cost-effectiveness of rituximab-based chemoimmunotherapy for primary cold agglutinin disease. Blood Res. 2025;60(1):59. https:\/\/doi.org\/10.1007\/s44313-025-00109-y.","journal-title":"Blood Res"},{"issue":"14","key":"169_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","volume":"384","author":"A R\u00f6th","year":"2021","unstructured":"R\u00f6th A, Barcellini W, D\u2019Sa S, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384(14):1323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2027760.","journal-title":"N Engl J Med"},{"issue":"9","key":"169_CR29","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1182\/blood.2021014955","volume":"140","author":"A R\u00f6th","year":"2022","unstructured":"R\u00f6th A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;140(9):980\u201391. https:\/\/doi.org\/10.1182\/blood.2021014955.","journal-title":"Blood"},{"issue":"6","key":"169_CR30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/bloodadvances.2019001321","volume":"4","author":"G Gelbenegger","year":"2020","unstructured":"Gelbenegger G, Schoergenhofer C, Derhaschnig U, et al. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv. 2020;4(6):997\u20131005. https:\/\/doi.org\/10.1182\/bloodadvances.2019001321.","journal-title":"Blood Adv"},{"issue":"19","key":"169_CR31","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1182\/bloodadvances.2022009318","volume":"7","author":"A R\u00f6th","year":"2023","unstructured":"R\u00f6th A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023;7(19):5890\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2022009318.","journal-title":"Blood Adv"},{"issue":"4","key":"169_CR32","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1111\/bjh.18289","volume":"198","author":"G Gelbenegger","year":"2022","unstructured":"Gelbenegger G, Jaeger U, Fillitz M, et al. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: a phase I, open-label, extension trial. Br J Haematol. 2022;198(4):e59\u201362. https:\/\/doi.org\/10.1111\/bjh.18289.","journal-title":"Br J Haematol"},{"issue":"8","key":"169_CR33","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ajh.26965","volume":"98","author":"A R\u00f6th","year":"2023","unstructured":"R\u00f6th A, Barcellini W, D\u2019Sa S, et al. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease. Am J Hematol. 2023;98(8):1246\u201353. https:\/\/doi.org\/10.1002\/ajh.26965.","journal-title":"Am J Hematol"},{"issue":"20","key":"169_CR34","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.2021012039","volume":"138","author":"M Jalink","year":"2021","unstructured":"Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome. Blood. 2021;138(20):2002\u20135. https:\/\/doi.org\/10.1182\/blood.2021012039.","journal-title":"Blood"},{"issue":"11","key":"169_CR35","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","volume":"8","author":"M Jalink","year":"2024","unstructured":"Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622\u201334. https:\/\/doi.org\/10.1182\/bloodadvances.2024012585.","journal-title":"Blood Adv"},{"issue":"5","key":"169_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","volume":"132","author":"G Rossi","year":"2018","unstructured":"Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132(5):547\u201350. https:\/\/doi.org\/10.1182\/blood-2018-03-835413.","journal-title":"Blood"},{"issue":"8","key":"169_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2023022153","volume":"143","author":"S D'Sa","year":"2024","unstructured":"D\u2019Sa S, Vos JMI, Barcellini W, et al. Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study. Blood. 2024;143(8):713\u201320. https:\/\/doi.org\/10.1182\/blood.2023022153.","journal-title":"Blood"},{"issue":"2","key":"169_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ajh.70147","volume":"101","author":"A R\u00f6th","year":"2026","unstructured":"R\u00f6th A, Barcellini W, Ademokun C, et al. Iptacopan for immune thrombocytopenia and cold agglutinin disease: a global phase 2 basket clinical trial. Am J Hematol. 2026;101(2):242\u201354. https:\/\/doi.org\/10.1002\/ajh.70147.","journal-title":"Am J Hematol"},{"issue":"10","key":"169_CR39","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/blood.2019003809","volume":"137","author":"S Berentsen","year":"2021","unstructured":"Berentsen S. How I treat cold agglutinin disease. Blood. 2021;137(10):1295\u2013303. https:\/\/doi.org\/10.1182\/blood.2019003809.","journal-title":"Blood"},{"issue":"7","key":"169_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/17474086.2024.2366540","volume":"17","author":"W Barcellini","year":"2024","unstructured":"Barcellini W, Fattizzo B. The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease. Expert Rev Hematol. 2024;17(7):287\u201394. https:\/\/doi.org\/10.1080\/17474086.2024.2366540.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"169_CR41","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","volume":"75","author":"LS Evans","year":"2023","unstructured":"Evans LS, Lewis KE, DeMonte D, et al. Povetacicept, an Enhanced Dual APRIL\/BAFF antagonist that modulates b lymphocytes and pathogenic autoantibodies for the treatment of lupus and other b cell-related autoimmune diseases. Arthritis Rheumatol. 2023;75(7):1187\u2013202. https:\/\/doi.org\/10.1002\/art.42462.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"169_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00169-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:52:50Z","timestamp":1788515570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00169-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00169-8","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"25 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a review of previously published literature and does not include any new studies involving human participants or animals performed by the author.Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"49"}}